The effect of SENV infection on chronic viral hepatitis is not very clear till now. Information regarding SENV infections in the Egyptian population where hepatitis viruses are prevalent is limited to a certain extent. We aimed to determine the frequency of SENV and its genotypes H and D in Egyptian patients with chronic hepatitis B (CHB) or C (CHC) and to study its possible role in the progression of liver disease. A total of 112 patients with chronic hepatitis (18 CHB and 94 CHC) were subjected to clinical assessment, laboratory and histological examinations. DNA from sera was extracted and SENV DNA was amplified by polymerase chain reaction. SENV DNA was detected in 28.6% of patients with chronic hepatitis (32/112). The percentage was 33.3 and 27.7% in CHB and CHC patients respectively. SENV-H was detected more frequently than SENV-D genotype. For CHC patients without cirrhosis (n=44), SENV was negative in 90.9% (40/44) compared to 9.1% (4/44) SENV positive giving a statistically significant difference (<0.001). A significantly higher percentage of patients showed twofold or more increase in the aspartate transaminase (AST) and alkaline phosphatase (ALP) among SENV negative CHC patients compared to SENV positive patients (P=0.04 , 0.03 respectively). In cirrhotic patients (n=58), both the levels of ALP and serum total bilirubin were significantly higher in SENV negative compared to SENV positive patients (P values were 0.01). For CHB patients, no statistically significant difference was detected regarding any of the studied parameters. We conclude that SENV does not worsen the progression of chronic viral hepatitis. This may reflect a possible protective effect of SENV in CHC patients which needs to be emphasized by further larger studies.
INTRODUCTION
The SEN virus (SENV) was considered to be a member of the family Circoviridae, genus Anellovirus, a group of non-enveloped, circular DNA viruses that also included the Torque teno (TTV) and its variants SANBAN, YONBAN, TUS01, and PMV (Sugiura et al., 2004) . Now Anelloviridae is a highly divergent family of viruses that has three genera of anelloviruses capable of infecting humans: torque teno virus (TTV; Alphatorquevirus), torque teno minivirus (TTMV; Betatorquevirus), and torque teno midivirus (TTMDV; Gammatorquevirus) (Biagini, 2009) .
SENV has a different geographic distribution and is fairly common around the world. Its prevalence has been found to vary in different populations (Tezcan et al., 2009) . Phylogenetic analysis of SENV has demonstrated nine different genotypes: SENV-A to SENV-I which show 15-50% sequence diversities among them (Kojima et al., 2003) . SENV-H and SENV-D genotypes were extremely associated with non-A to E hepatitis (Schroter et al., 2003) .
Although not all transmission routes have been identified (Tezcan et al., 2009 ), yet it was reported that SENV-D/H could be transmitted by both parenteral and non-parenteral routes (faecal oral) (Umemura et al., 2001) . Iatrogenic means in hospital setting is reported as a mode of transmission (Sagir et al., 1994) . In addition, vertical transmission from mother to fetus does occur (Pirovano et al., 2002) .
The prevalence of SENV has been investigated in patients with various forms of liver disease in many countries. SENV infection is frequently observed in patients with hepatitis B virus (HBV) (23 to 59%), hepatitis C virus (HCV) (22 to 89%), and in patients with hepatitis of unknown etiology (Schreter et al., 2006) .
SENV may cause persistant infection that may exceed one year and has been documented as long as 12 years (Umemura et al., 2002) . The role of SENV infection and the clinical significance were studied in patients with non A-E hepatitis or other viral hepatitis but the results are not very clear and are inconsistent to some extent and even show contradictory results (Wang et al., 2007; Cakaloglu et al., 2008) . That is to say, coinfection with hepatitis B virus (HBV), or hepatitis C virus (HCV) has been reported to be associated with severe and progressive liver disease (Jardi et al., 2001) . However, others reported that SENV was found to have no established pathogenicity and the exact role of this virus in the pathogenesis of liver diseases, including acute and chronic hepatitis, cirrhosis and the development of hepatocellular carcinoma (HCC) remains to be verified (Rizvi et al., 2013) . Others suggested a protective role of SENV against HCV (Umemura et al., 2001) . Information regarding SENV infections in the Egyptian population where HBV and HCV are prevalent is limited to a certain extent.
It has been stated that Egypt has the highest prevalence of hepatitis C worldwide and the epidemic will soon peak (Yahia, 2011) . Overall, HCV prevalence among blood donors ranged between 5-25%, and among other general population groups between 0-40%. HCV prevalence among multi-transfused patients ranged between 10-55%, and among high risk populations reached up to 85% (Mohamoud et al., 2013) . For HBV, the prevalence in Egypt was found to be 5% (Awadalla et al., 2011) .
The aim of present study was to determine the frequency of SENV and its genotypes H and D in Egyptian patients with chronic hepatitis B (CHB) or C (CHC) and to study its possible role in the progression of liver disease in such patients.
MATERIALS AND METHODS

Study design
This cross sectional study was done in Assiut University Hospital after being approved by the Ethical Committee of the Faculty of Medicine, Assiut University. A verbal consent was also taken from the patients enrolled in the study.
Patients
A total of 112 patients with CHC or CHB were included in the study during a six months period (from June to December 2013). Patients were admitted to the department of Tropical Medicine and Gastroenterology, Assiut University. They were divided into 2 groups; patients with CHC (n=94) and CHB (n=18). None of the patients had a history of receiving antiviral therapy. For all patients, thorough clinical assessment, abdominal ultrasonography, laboratory tests and liver histopathology were done. The severity of cirrhosis was assessed by Child-Pugh classification (Child and Turcotte, 1964; Pugh et al., 1973) We defined chronic hepatitis as persistent or intermittent elevation in alanine transaminase (ALT) or aspartate transaminase (AST) levels for more than 6 months with the presence of anti-HCV antibodies and positive serum HCV RNA for chronic hepatitis C (Anwar et al., 2006) , positive HBsAg and positive serum HBV DNA for chronic hepatitis B and by liver biopsy showing chronic hepatitis with moderate or severe necroinflammation (Huntzinger, 2009 ).
Healthy controls
The control group included 20 healthy individuals of comparable age among which 12 (60%) were men and 8 (40%) women; their mean age being 45 years ± 3.6. These individuals were negative for HBsAg and anti-HCV.
Laboratory tests
Five milliliters blood was withdrawn from each subject under complete aseptic conditions. Sera were separated and stored frozen at -20°C until analysis. For all serum samples, the following laboratory tests were performed: Liver function tests (aspartateaminotransferase (AST), alanine transaminase (ALT), Alkaline phosphatase (ALP), albumin, bilirubin and prothrombin time); Serological tests for HBV and HCV infection were determined by the ARCHITECT system for anti HCV and HBs Ag which is a chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of antibodies to hepatits C virus (Anti-HCV) and HBs Ag in human serum and plasma (Abbott GmbH, Wiesbaden-Delkenheim, Germany); HBV DNA was quantified by Real time PCR using artus HBV TM PCR kit (Applied Biosystems) and HCV RNA was quantified by Taq Man Assay Reagents (Applied Biosystems) using the 7500 fast Real Time PCR system; Polymerase chain reaction for SENV DNA.
Extraction of SENV DNA from serum
DNA was extracted from 200 μL serum using QIAamp DNA blood mini kit (Qiagen, Cat. No. 51104-Germany) according to the manufacturer's instructions
Amplification and detection
SENV DNA (349 bp) was detected by PCR according to Kojima et al. (2003) . SENV common primers were used and were as following: forward primer AI-1F (5'-TWC YCM AAC GAC CAG CTA GAC CT-3'; W = A or T, Y = C or T, M = A or C), and reverse primer AI-1R (5'-GTT TGT GGT GAG CAG AAC GGA-3'). A 25 μl PCR mixture was used and consisted of: PCR master mix (12.5 μl), forward primer (AI -1F) (0.5 μl), reverse primer (AI -1R) (0.5 μl), distilled water (3 μl), extracted DNA (8.5 μl). Amplification was performed for 40 cycles, each included denaturation at 94ºC for 30 s, annealing at 52ºC for 30 s and extension at 72ºC for 60 s. This was followed by a final extension at 72ºC for 10 min to complete strand synthesis. SENV-D DNA (231 bp) and SENV-H DNA (230bp) were detected by PCR with SENV specific primers, as previously described (Kojim et al., 2003) . Type-specific primers D10S and L2AS and primers C5S and L2AS were used for SENV-D and SENV-H detections, respectively (Kojima et al., 2003) . PCR mixture of 25 μl consisted of: PCR master mix (12.5 μl), forward primer (D10S) for SENV-D or (C5S) for SENV-H (0.5 μl), reverse primer (L2AS) (0.5 μl), distilled water (3 μl), extracted DNA (8.5 μl). PCR conditions for SENV-D and SENV-H genotypes were the same. Amplification was performed for 40 cycles, each included denaturation at 94ºC for 30 s, annealing for SENV-D at 58ºC for 30 s, for SENV-H at 50ºC for 30 s and extension at 72ºC for 60 s. Then, 10 min final extension at 72ºC was used to complete strand synthesis. PCR was performed in a DNA thermal cycler (HYBAID-PCR Express). The PCR products were separated using 1.5% agarose gel, stained with ethidium bromide, and visualised under a UV illuminator.
Liver histology
Liver biopsies were taken percutaneously with a 1.4 mm diameter Menghini needle and consisted of 3-5 mm long liver tissue cores. Biopsies were promptly fixed in 10% formalin, processed and embedded in paraffin blocks. Four µm sections were cut and slides were staind by hematoxylin-eosin and reticulin stains using the standard techniques. Modified hepatitis activity index (METAVIR) grading and staging were determined for each case according to the scheme given by Ishak et al. (1995) .
Statistical data analysis
The statistical analysis was performed using statistical package for social sciences (SPSS) version 17.0 for Windows (SPSS, Chicago IL, U.S.A). Continuous data were expressed as means ± standard deviation (SD) and compared using Student's T test. Categorical variables were expressed as percentage and compared using chisquare (χ2) test and Fisher's exact probability test. A P value of ≤ 0.05 was considered significant.
RESULTS
Chronic HCV patients (n= 94) included 74 males and 20 females with a mean age of 47.2 ± 10.9 and chronic HBV patients (n=18) included 10 males and 8 females with a mean age of 48.4 ± 12.8. Cirrhosis was found in 50 patients with CHC (53.2%) and in 8 patients with CHB (44.4%). SENV DNA was detected in 28.6% of patients with chronic liver disease (32/112) and in 15% (3/20) of the control group but without a statistical significant difference (P = 0.21). Table 1 shows the frequency of SENV and its genotypes H/D among the studied groups. SENV was detected in 27.7% of CHC cases (26/94) and in 33.3% of CHB patients (6/18). The commonest genus identified in both groups was SENV H in 38.5 and 33.3% respectively. However, SENV D was the only genus identified in controls (100%).
Combined SENVH /D were found in patients groups not amongst the controls. Analysis of PCR products for the presence of SENV-H and SENV-D DNA on agarose gel is shown in Figures 1 and 2 .
On comparing the characteristics of patients with chronic hepatitis in relation to SENV viraemia (Table 2) , we found that among patients with CHC without cirrhosis (n=44), SENV was negative in 90.9% (40/44) compared to 9.1% (4/44) SENV positive that was highly statistically significant (P < 0.001). On the other hand, no significant differences were found between SENV positive and negative CHB patients regarding any of the studied characteristics.
Regarding markers of severity of disease, we found that among patients with CHC without cirrhosis, the percentage of patients showing twofold increase in AST and ALT were significantly higher in SENV negative compared to SENV positive patients (p=0.04 and 0.03 respectively). All the remaining clinical, laboratory and histological features were not of statistical significant difference as shown in Table 3 . Concerning cirrhotic patients, the level of ALP and serum total bilirubin were significantly higher in patients without SENV viraemia compared to patients with SENV infection (p values were 0.01 for both). Other parameters regarding laboratory findings, severity of liver disease using Child-Pugh classification and liver cirrhosis related complications showed no significant differences (Table 4) .
DISCUSSION
Patients with SENV infection develop a persistent infection that exceeds one year in approximately 45% and has been documented as long as 12 years (Umemura et al, 2002) . The exact interaction of SENV with HCV and HBV is unclear (Tahan et al., 2003) .
SENV-H and D genotypes have been found at various rates in different populations and the role of SEN-V regarding the pathogenesis of liver disease is not yet known (Mu et al., 2004) . In the present study, SENV was detected in a considerable percentage of chronic hepatitis patients with genotype H being the most prevalent. We reported SENV DNA in 28.6% of patients with chronic liver disease (27.7% in CHC, 33.3% in CHB) and in 15% of the control group (3/20). The percentage of SENV among CHC patients is generally in accordance with the average of percentages recorded in different regions in Egypt that ranged from 13.5 to 49% (Kholeif and Fayez, 2008; Omar et al., 2008) . Internationally, the SENV percentage was around 21% and reaching up to 69% in many previous studies (Kojima et al., 2003; Schroter et al., 2003; Yoshida et al., 2002) . For the control group, we found the percentage of SENV to be 15% (3/20) . This is in the range reported by previous Egyptian studies where it was found to be 16 and 20% among the controls (Omar et al., 2008; Sayed et al., 2006; Mohamed et al., 2011) .
Regarding the CHC group, we reported SENV H, SENV D and combined H/D in 38.5, 15.4 and 11.5% respectively. This is comparable to the results of a previous Egyptian study, where the percentages were 42% (18/43), 16% (7/43) and 9% (4/43) respectively (Kholeif and Fayez, 2008) . In agreement, many studies reported SENV-H to be more prevalent than SENV-D (Tezcan et al., 2009; Sayed et al., 2006; Loutfy et al., 2009) . In Turkey, SENV-H DNA was found to be positive in 23.3% (7/30) of patients with CHC (Cakaloglu et al., 2008) . On the other hand, SENV D was more prevalent in CHC patients (8.1%, 6/74) compared to only 5.4% (4/74) SENV H (Omar et al., 2008) .
Concerning the CHB group, we reported SENV in 33.3% with SENV H again being the predominant genotype (33.3%) compared to only 16.7% for SENV D. Very limited Egyptian studies were found regarding
